Closed-loop pancreas system aces trial

Closed-loop pancreas system aces trial

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Tandem and Dexcom system aces closed-loop pancreas trial for type 1 diabetes, but doesn’t appear to break new ground over existing market competitor.

A clinical trial of an artificial closed-loop pancreas system, designed for 24-hour monitoring and regulation of blood-sugar levels, has found the system to be more effective than existing treatments for type 1 diabetes.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Ben Turner

Staff Writer

Ben Turner is a writer and journalist based in London. He graduated in 2015 with a Master’s degree in Physics. He is particularly interested in the translation of early scientific discoveries into cutting-edge tech.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE